Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
Rhea-AI Summary
Polyrizon (Nasdaq: PLRZ) announced a comparative pre-clinical study showing its naloxone nasal formulation achieved 94.6% (±4.0%) deposition in the nasal vestibule and upper turbinate versus 79.6% (±3.0%) for a commercial reference product.
The study used a validated silicone nasal cast and quantitative imaging; Polyrizon reported lower lower-turbinate deposition (5.4% vs. 20.4%), which may reduce posterior runoff and improve dosing consistency for intranasal systemic delivery.
Positive
- Vestibule/upper turbinate deposition 94.6% (±4.0%) vs 79.6% reference
- Lower turbinate deposition reduced to 5.4% from 20.4%
- Validated in vitro method using Koken® LM-005 silicone nasal cast
Negative
- Pre-clinical stage study; no human clinical data yet
- In vitro model limitation may not fully predict in vivo absorption or clinical outcomes
Key Figures
Market Reality Check
Peers on Argus
PLRZ fell 3.29% while key biotech peers were mixed: TTNP -3.96%, ADTX -3.31% (scanner later showed strength), ENSC -1.17%, SILO +13.71%, SXTP +0.99%, suggesting stock-specific dynamics rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Product branding update | Positive | +0.4% | Unveiled NASARIX™ branding and trademark clearance with strong preclinical allergy data. |
| Feb 10 | Acquisition intent update | Positive | +3.9% | Detailed terms of planned 51% Arrow Aviation stake with revenue and EBITDA profile. |
| Feb 06 | Development agreement | Positive | +3.3% | Signed deal to develop intranasal MEAI formulation with Clearmind Medicine. |
| Feb 04 | Acquisition announcement | Neutral | -15.2% | Initial MOU to acquire 51% of Arrow Aviation and enter private aviation sector. |
| Jan 22 | Regulatory pathway step | Positive | -2.0% | Initiated FDA-aligned human factors/usability study for NASARIX™ allergy blocker. |
Recent fundamentally positive updates have often seen modest gains, but some strategic moves and development milestones drew negative reactions.
Over the last few months, Polyrizon reported multiple intranasal platform milestones and a strategic expansion initiative. Branding and usability work for NASARIX™ (e.g., the human factors study on Jan 22, 2026 and branding news on Feb 17, 2026) framed PL-14’s path toward clinical trials in Q3 2026. The company also announced plans to acquire a 51% stake in Arrow Aviation, with initial disclosure on Feb 4, 2026 drawing a sharp negative move despite similar terms reiterated on Feb 10, 2026. Today’s naloxone deposition data extends the intranasal drug-delivery narrative built in these prior updates.
Regulatory & Risk Context
An effective Form F-3 shelf filed on Nov 7, 2025 allows Polyrizon to offer up to $50,000,000 of securities, providing flexibility to raise capital via equity, warrants, or units as detailed in future prospectus supplements.
Market Pulse Summary
This announcement highlights pre-clinical evidence that Polyrizon’s naloxone formulation achieved 94.6% deposition in the highly vascularized upper nasal region versus 79.6% for a commercial product, with reduced lower turbinate deposition. It adds to a series of updates on the company’s intranasal platform, including NASARIX™ and an MEAI collaboration. Investors may watch for translation of these deposition advantages into clinical outcomes, any follow-on regulatory steps, and how capital needs under the $50,000,000 shelf are managed.
Key Terms
naloxone medical
intranasal medical
nasal vestibule medical
AI-generated analysis. Not financial advice.
Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product.
The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. The laboratory specializes in the research and development of intranasally administered technologies.
The evaluation was performed using a validated silicone nasal cast model (Koken® LM-005) combined with quantitative image analysis. Results demonstrated that Polyrizon’s formulation achieved significantly higher deposition in the nasal vestibule region compared to the commercial reference product.
Key Findings:
- Polyrizon’s advanced nasal formulation achieved
94.6% (±4.0% ) deposition in the nasal vestibule and upper turbinate, a highly vascularized region that may support rapid systemic absorption and potentially enhance the onset and bioavailability of intranasally administered drugs. - In comparison, the reference commercial product delivered only 79.6% (±
3.0% ) to the same nasal cavity area. - Polyrizon’s formulation also showed significantly lower deposition in the lower turbinate region (
5.4% vs.20.4% for the commercial product), potentially reducing posterior runoff and unintended drainage toward the nasopharynx, which may support improved dosing consistency and systemic delivery efficiency.
The upper/anterior nasal region (upper turbinate and vestibule) is highly vascularized and plays a critical role in rapid systemic drug absorption. Enhanced and reproducible targeting of this region suggests that Polyrizon’s Trap & Target™ technology enables controlled regional deposition within the nasal cavity.
“This evaluation demonstrates the ability of our platform technology to modulate and control nasal deposition patterns compared to an established commercial product,” said Tomer Izraeli, CEO of Polyrizon. “We believe that these results further validate our formulation-engineering approach and strengthen the differentiation of our intranasal platform.”
Polyrizon continues to advance its naloxone program as part of its broader intranasal platform strategy.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses continuing to advance its naloxone program as part of its broader intranasal platform strategy. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
IR@polyrizon-biotech.com
FAQ
What nasal deposition results did Polyrizon (PLRZ) report on Feb 26, 2026 for its naloxone formulation?
How might PLRZ's higher vestibule deposition affect naloxone absorption and onset?
Did Polyrizon (PLRZ) test its naloxone formulation in humans or clinical trials?
What methodological approach did Polyrizon (PLRZ) use to compare deposition versus the commercial product?
What are the potential drawbacks of PLRZ's naloxone study results for investors?
